Lancet J, et al. Lancet Haematol. 2021: The 5-year analysis of Study 301

In this final analysis of the Phase III pivotal trial for Vyxeos Liposomal, the authors present the OS outcomes for the overall ITT population, as well as a breakdown of the results by patient age, cytogentic profile, prior HMA exposure, consolidation therapy, and more.

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Cytogenetics Safety Vyxeos Liposomal Data


Adverse events should be reported. Reporting forms and information for the UK can be found at

For Ireland, reporting forms and information can be found at:

Adverse events should also be reported to Jazz Pharmaceuticals at

UK-VYX-2100177 | September 2021